Inhibition of collagen type I synthesis by skin fibroblasts of graft versus host disease and scleroderma patients: Effect of halofuginone

Biochemical Pharmacology

Volumn 52, Issue 7, 1996, Pages 1057-1063

  Halevy, Orna ^a   Nagler, Arnon ^b   Levi Schaffer, Francesca ^a   Genina, Olga ^c   Pines, Mark ^c  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c VOLCANI CENTER   (Israel)

Author keywords

autoimmune diseases; collagen 1(I); fibroblasts; fibrosis; plant alkaloid; TGF

Indexed keywords

ALKALOID; COLLAGEN TYPE 1; CYCLOHEXIMIDE; DACTINOMYCIN; HALOFUGINONE; MESSENGER RNA; PROTEIN SYNTHESIS INHIBITOR; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ARTICLE; AUTOIMMUNITY; CELL CULTURE; COLLAGEN SYNTHESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ETIOLOGY; FIBROSIS; GENE CONTROL; GENE EXPRESSION; GENETIC TRANSCRIPTION; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SCLERODERMA; SKIN FIBROBLAST;

EID: 0030580036     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(96)00427-3     Document Type: Article

References (40)

1. 1. Kivirikko KI, Collagens and their abnormalities in a wide spectrum of diseases. Ann Med 25: 113-126, 1993.
2. 2. Cunliffe CJ, Franklin TJ, Hales NJ and Hill GB, Novel inhibitors of prolyl 4-hydroxylase. 3. Inhibition by substrate analogue N-oxaloglycine and its derivatives. J Med Chem 35: 2652-2658, 1992.
3. 3. Karvonen K, Ala-Kokko L, Pihlajaniemi T, Helaakoski T, Henke S, Gunzler V, Kivirikko KI and Savolainen ER. Specific inactivation of prolyl 4-hydroxylase and inhibition of collagen synthesis by oxaproline-containing peptides in cultured human skin fibroblasts. J Biol Chem 265: 8415-8419, 1990.
4. 4. Hanauske-Abel HM, Prolyl-4-hydroxylase, a target enzyme for drug development. Design of suppressive agents and the in vitro effects of inhibitors and proinhibitors. J Hepatol 13: S8-S16, 1991.
5. 5. Delany AM and Brinckerhoff CE, The synthetic retinoid (4-hydroxyphenyl) retinamide decreases collagen expression in vitro and in the tight-skin mouse. Arthr Rheum 36: 983-993, 1993.
6. 6. Granot I, Bartov I, Plavnik I, Wax E, Hurwitz S and Pines M, Increased skin tearing in broilers and reduced collagen synthesis in skin in vivo and in vitro in response to the coccidiostat halofuginone. Poult Sci 70: 1559-1563, 1991.
7. 7. Granot I, Hurwitz S, Halevy O and Pines M, Halofuginone: an inhibitor of collagen type I synthesis. Biochim Biophys Acta 1156: 107-112, 1993.
8. 8. Choi ET, Callow AD, Sehgal NL, Brown DM and Ryan US, Halofuginone, a specific collagen type I inhibitor, reduces anastomotic intima hyperplasia. Arch Surg 130: 257-261, 1995.
9. 9. Krieg TM and Meurer M, Systemic sclerosis: clinical and pathophysiological aspects. J Am Acad Dermatol 18: 457-481, 1988.
10. 10. Haustein UF, Herrmann K and Bohme HJ, Pathogenesis of progressive systemic sclerosis. Int J Dermatol 25: 286-293, 1986.
11. 11. Rodnan GP, Lipinski E and Luksick J, Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthr Rheum 22: 130-140, 1979.
12. 12. Leroy EC, Increase collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblasts. J Clin Invest 54: 880-889, 1974.
13. 13. Buckingham RB, Prince RK, Rodan GP and Taylor F, Increase collagen accumulation in dermal fibroblast cultures from patients with progressive systemic sclerosis (scleroderma). J Lab Clin Invest 92: 5-21, 1978.
14. 14. Jimenez S, Feldman G, Bashey R, Bienkowski R and Rosenbloom J, Coordinate increase in the expression of type I and III collagen genes in progressive systemic sclerosis fibroblasts. Biochem J 237: 837-843, 1986.
15. 15. Herrmann K, Heckmann M, Kulozik M, Haustein UF and Krieg T, Steady-state mRNA levels of collagens I, III, fibronectin, and collagenase in skin biopsies of systemic sclerosis patients. J Invest Dermatol 97: 219-222, 1991.
16. 16. Ohta A and Uitto J, Procollagen gene expression by scleroderma fibroblasts in culture. Inhibition of collagen production and reduction of pro alpha 1(I) and pro alpha 1(III) collagen messanger RNA steady state levels by retinoids. Arthr Rheum 30: 404-411, 1987.
17. 17. Graze RP and Gale RP, Chronic graft-versus-host disease: A syndrome of disordered immunity. Am J Med 66: 611-619, 1979.
18. 18. Chosidow O, Bagot M, Vernant JP, Roujeau YC, Cordonnier C, Kuenz M, Wechsler J, Andre CJ, Touraine RE and Rovuz JJ, Sclerodermatous chronic graft-versus-host disease. Analysis of seven cases. J Am Acad Dermatol 26: 49-53, 1992.
19. 19. Levi-Schaffer F, Nagler A, Slavin S, Knopov V and Pines M, Inhibition of collagen synthesis and changes in skin morphology in murine graft-versus-host disease and tight skin mice: effects of halofuginone. J Invest Dermatol 106: 84-88, 1995.
20. 20. Chu M, DeWet W, Bernard M and Ramirez F, Fine structural analysis of the human pro-alpha 1(I) collagen gene. J Biol Chem 260: 2315-2320, 1985.
21. 21. Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon RP, McDonald GB, Schubert MM, Atkinson K and Thomas ED, Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 57: 267-276, 1981.
22. 22. Pines M, Granot I and Hurwitz S, Cyclic AMP-dependent inhibition of collagen synthesis in avian epiphyseal cartilage cells: effect of chicken and human parathyroid hormone and parathyroid hormone-related peptide. Bone Min 9: 23-33, 1990.
23. 23. Granot I, Halevy O, Hurwitz S and Pines M, Growth hormone and insulin growth factor I regulate collagen gene expression and extracellular collagen in cultures of avian skin fibroblasts. Mol Cell Endocrinol 80: 1-9, 1991.
24. 24. Chomczynski P and Sacchi N, Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987.
25. 25. Feinberg AP and Vogelstein B, A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 132: 6-13, 1983.
26. 26. Vuorio T, Kahari VM, Black C and Vuorio E, Expression of osteonectin, decorin, and transforming growth factor β1 genes in fibroblasts cultures from patients with systemic sclerosis and morphea. J Rheumatol 18:247-251, 1991.
27. 27. Rhodes K, Rippe RA, Umezawa A, Nehls M, Brenner DA and Breindl M, DNA methylation represses the murine alpha 1(I) collagen promoter by an indirect mechanism. Mol Cell Biol 14: 5950-5960, 1994.
28. 28. Mauch C, Eckes B, Hunzelmann N, Oono T, Kozlowska E and Krieg T, Control of fibrosis in systemic scleroderma. J Invest Dermatol 100: 92S-96S, 1993.
29. 29. Vuorio T, Makela JK and Vuorio E, Activation of type I collagen genes in cultured scleroderma fibroblasts. J Cell Biochem 28: 105-113, 1985.
30. 30. McWhirter A, Colosetti P, Rubin K, Miyazono K and Black C, Collagen type I is not under autocrine control by transforming growth factor-β1 in normal and scleroderma fibroblasts. Lab Invest 71: 885-894, 1994.
31. 31. Parker MI, Judge K and Gevers W, Loss of type I procollagen gene expression in SV40-transformed human fibroblasts is accompanied by hypermethylation of these genes. Nucleic Acid Res 10: 5879-5891, 1982.
32. 32. Thompson JP, Simkevich CP, Holness MA, Kang AH and Raghow RR, In vitro methylation of the promoter and enhencer of pro alpha 1(I) collagen gene leads to its transcriptional inactivation. J Biol Chem 266: 2549-2556, 1991.
33. 33. Simkevich CP, Thompson JP, Poppleton H and Raghow R, The transcriptional tissue specificity of the human proα1(I) collagen gene is determined by a negative cis-regulatory element in the promoter. Biochem J 286: 179-185, 1992.
34. 34. Jimenez S, Varga J, Olsen A, Li L, Diaz A, Herhal J and Koch J, Functional analysis of human α1(I) procollagen gene promoter: differential activity in collagen-producing and nonproducing cells and response to transforming growth factor β1. J Biol Chem 269: 12684-12691, 1994.
35. 35. Hatamochi A, Paterson B and de Crombrugghe B, Differential binding of a CCAAT DNA binding factor to the promoters of the mouse alpha 2(I) and alpha 1(III) collagen genes. J Biol Chem 261: 11310-11314, 1986.
36. 36. Boast SM, Su W, Ramirez F, Sanchez M and Avvedimento EV, Functional analysis of cis-acting DNA sequences controlling transcription of the human type I collagen genes. J Biol Chem 265: 13351-13356, 1990.
37. 37. Karsenty G and de Crombrugghe B, Two different negative and one positive regulatory factors interact with a short promoter segment of the α1(I) collagen gene. J Biol Chem 265: 9934-9942, 1990.
38. 38. Rippe RA, Lorenzen S, Brenner DA and Breindel M, Regulatory elements in the 5′-flanking region and the first intron contribute to transcriptional control of the mouse alpha 1 type I collagen gene. Mol Cell Biol 9: 2224-2227, 1989.
39. 39. Bedalov A, Breault DT, Sokolov BP, Lichtler AC, Bedalov I, Clark SH, Mack K, Khillan JS, Woody CO, Kream BE and Rowe D, Regulation of the α1(I) collagen promoter in vascular smooth muscle cells. Comparison with other α1(I) collagen-producing cells in transgenic animals and cultured cells. J Biol Chem 269: 4903-4909, 1994.
40. 40. Palvin D, Lichtler AC, Bedalov A, Kream BE, Harrison JR, Thomas HF, Gronowicz GA, Clark SH, Woody CO and Rowe DW, Differential utilization of regulatory domains within the α1(I) collagen promoter in osseous and fibroblastic cells. J Cell Biol 116: 227-236, 1992.